Mercados españoles cerrados

Chimerix, Inc. (CMRX)

NasdaqGM - NasdaqGM Precio en tiempo real. Divisa en USD
Añadir a la lista de favoritos
1,0600+0,0500 (+4,95%)
Al cierre: 04:00PM EDT
1,1000 +0,04 (+3,77%)
Después del cierre: 07:48PM EDT

Chimerix, Inc.

2505 Meridian Parkway
Suite 100
Durham, NC 27713
United States
919-806-1074
https://www.chimerix.com

Sector(es)Healthcare
SectorBiotechnology
Empleados a tiempo completo72

Ejecutivos clave

NombreTítuloPagaEjecutadoAño de nacimiento
Mr. Michael T. Andriole M.B.A.CEO, President & Director592,95kN/A1973
Dr. Allen S. Melemed M.B.A., M.D.Chief Medical Officer605,29kN/A1964
Ms. Michelle LaSpalutoChief Financial OfficerN/AN/A1975
Mr. Thomas J. RigaChief Operating & Commercial OfficerN/AN/A1976
Mr. David Jakeman CPAVP of Accounting & FinanceN/AN/A1978
Dr. Joshua E. Allen Ph.D.Chief Technology OfficerN/AN/AN/A
Dr. Michael A. Alrutz J.D., Ph.D.Senior VP, General Counsel & Corporate Secretary619,5kN/A1970
Dr. Roy W. Ware MBA, Ph.D.Chief Manufacturing Technology OfficerN/AN/AN/A
Dr. Pablo Lee M.D.Head of Medical AffairsN/AN/AN/A
Los importes son a partir de 31 de diciembre de 2022 y los valores de compensación son para el último año fiscal que finaliza en esa fecha. Paga es el salario, las bonificaciones, etc. Ejecutado es el valor de las opciones ejecutadas durante el año fiscal. Divisa en USD.

Descripción

Chimerix, Inc., a biopharmaceutical company, develops medicines to improve and extend the lives of patients facing deadly diseases. Its pipeline products include ONC201 a program that is in Phase 3 clinical trial for treating patients with H3 K27M-mutant diffuse glioma, as well as in Phase 2 clinical trial for the treatment of rare neuroendocrine tumors; and ONC206, an imipridone, Dopamine Receptor D2 (DRD2) antagonist, and caseinolytic protease P (ClpP) agonist, which is in Phase 1 clinical trial for adult and pediatric patients with primary central nervous system tumors. The company also develops ONC212, an imipridone agonist of the orphan G protein-coupled receptors (GPCR) tumor suppressor GPR132, as well as ClpP for oncology indications; and CMX521, a nucleoside analog antiviral drug candidate for the treatment of SARS-CoV-2. It has license agreement with SymBio Pharmaceuticals to develop and commercialize TEMBEXA for human diseases other than orthopoxviruses, including smallpox. Chimerix, Inc. was incorporated in 2000 and is headquartered in Durham, North Carolina.

Gobierno corporativo

El ISS Governance QualityScore de Chimerix, Inc., a día 1 de marzo de 2024, es 8. Las puntuaciones base son Auditoría: 9; Tablero: 7; Derechos de los accionistas: 8; Compensación: 8.

Puntuación de gobierno corporativo cedida por Institutional Shareholder Services (ISS). Las puntuaciones indican un rango decil relativo al índice o región. Una puntuación decil de 1 indica un menor riesgo de gobierno, mientras que un 10 indica un riesgo de gobierno superior.